Park Ha Biological Technology stock rises on upcoming ticker symbol change
NORTH CHICAGO - AbbVie (NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of over $405 billion, announced Monday that its JAK inhibitor upadacitinib (RINVOQ) demonstrated superior efficacy compared to adalimumab (HUMIRA) in patients with moderate to severe rheumatoid arthritis who previously failed treatment with a TNF inhibitor. According to InvestingPro data, AbbVie maintains strong financial health with a robust gross profit margin of 71.25%.
The Phase 3b/4 SELECT-SWITCH trial, the first head-to-head study comparing TNF inhibitor cycling with switching to upadacitinib, showed that patients receiving upadacitinib 15 mg once daily achieved significantly higher rates of low disease activity and remission at 12 weeks compared to those receiving adalimumab 40 mg every other week.
According to the trial results, 43.3% of patients on upadacitinib achieved low disease activity (defined as DAS28-CRP≤3.2) versus 22.4% on adalimumab. Additionally, 28.4% of upadacitinib patients reached remission (DAS28-CRP
"Upadacitinib demonstrated superiority in achieving low disease activity and remission at week 12 in nearly twice as many patients compared to adalimumab," said Eduardo Mysler, lead study investigator and executive medical director at Organización Medica de Investigación, Argentina, according to the company’s press release.
The safety profile for both medications was consistent with previous studies, with no new safety concerns identified during the 12-week period. The most common adverse events included urinary tract infection, nasopharyngitis, and rheumatoid arthritis worsening. With revenue of $58.33 billion in the last twelve months and trading near its 52-week high, AbbVie continues to demonstrate market leadership. InvestingPro subscribers have access to 14 additional key insights and a comprehensive Pro Research Report, offering deeper analysis of AbbVie’s market position and growth potential.
The study enrolled 492 adult patients with moderate to severe rheumatoid arthritis who had an inadequate response or intolerance to a TNF inhibitor other than adalimumab. All patients were on a stable background of methotrexate.
Full results from the study are expected to be published in a medical journal and presented at future medical conferences, according to the company’s statement. With analysts predicting continued profitability and net income growth this year, AbbVie appears well-positioned to maintain its strong market presence. For detailed financial analysis and expert insights about AbbVie and 1,400+ other stocks, consider exploring InvestingPro’s comprehensive research tools and reports.
In other recent news, AbbVie has completed its acquisition of bretisilocin, a psychedelic compound from Gilgamesh Pharmaceuticals, which is in Phase 2 clinical development for major depressive disorder. This acquisition highlights AbbVie’s ongoing efforts to expand its treatment options in the mental health sector. Additionally, the U.S. Food and Drug Administration has approved an updated indication for AbbVie’s RINVOQ, allowing its use in treating ulcerative colitis and Crohn’s disease when TNF blockers are not advisable. Analysts at Raymond James have raised their price target for AbbVie to $250, maintaining an Outperform rating, based on positive prescription trends and strong second-quarter results.
Cantor Fitzgerald also reiterated its Overweight rating with a $250 price target, though it adjusted its earnings model to reflect tax impacts from a planned IPR&D charge. Conversely, Erste Group downgraded AbbVie from Buy to Hold, citing a reduction in the company’s full-year 2025 adjusted earnings per share guidance. These developments come as AbbVie prepares to release its third-quarter earnings report, with analysts closely watching for continued strong performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.